We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
An FDA advisory panel voted Wednesday in favor of the safety and efficacy of Paratek’s two NDAs for omadacycline tablets and omadacycline injection as treatments for community-acquired bacterial pneumonia (CAPB) and acute bacterial skin and skin structure infections (ABSSSI). Read More
An FDA advisory committee voted Tuesday in favor of the safety and effectiveness of Insmed’s NDA amikacin for treatment of nontubercuolous mycobacterial (NTM) lung disease for patients with limited treatment options. But the panel rejected it for adult patients as a whole. Read More
The FDA Tuesday finalized its recommendations on how drug sponsors submitting applications should control elemental impurities in their drug products. Read More
For a nonclinical toxicity assessment, the agency recommends that sponsors submit toxicity information for all components of the drug product formulation, heat-generated products and impurities. Read More
UK drug manufacturers will retain access to EU markets during the Brexit implementation period, the MHRA said in an update Monday, noting EU authorities will continue to recognize the UK’s manufacturing and distribution licenses as well as inspections. Read More